Aprea Therapeutics Inc. [APRE] stock is up 12.44 while the S&P 500 has fallen -0.17% on Thursday, 11/19/20. While at the time of this article, APRE ATR is sitting at 1.61. This stock’s volatility for the past week remained at 4.38%, while it was 7.88% for the past 30-day period. APRE has risen $2.61 from the previous closing price of $20.98 on volume of 0.28 million shares.

On 19, November 2020, Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference. According to news published on Yahoo Finance, Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.

Analyst Birdseye View:

The most recent analyst activity for Aprea Therapeutics Inc. [NASDAQ:APRE] stock was on June 22, 2020, when it was Initiated with a Neutral rating from H.C. Wainwright, which also raised its 12-month price target on the stock to $30. Before that, on September 29, 2020, JP Morgan Recapitulated a Neutral rating and elevated its amount target to $25. On April 21, 2020, Robert W. Baird Initiated an Outperform rating and boosted its price target on this stock to $45. On October 28, 2019, RBC Capital Mkts Initiated an Outperform rating and increased its price target to $33. On October 28, 2019, Morgan Stanley Initiated an Equal-weight rating and increased its price target to $23. On October 28, 2019, JP Morgan Initiated a Neutral rating and boosted its amount on this stock to $23.

In the past 52 weeks of trading, this stock has oscillated between a low of $19.67 and a peak of $53.11. Right now, the middling Wall Street analyst 12-month amount mark is $39.00. At the most recent market close, shares of Aprea Therapeutics Inc. [NASDAQ:APRE] were valued at $23.59. According to the average price forecast, investors can expect a potential return of 8.21%.

FUNDAMENTAL ANALYSIS

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 20.49 points at 1st support level, the second support level is making up to 20.01. But as of 1st resistance point, this stock is sitting at 21.23 and at 21.49 for 2nd resistance point.

Aprea Therapeutics Inc. [APRE] reported its earnings at -$0.58 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.76/share signifying the difference of 0.18 and 23.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.78 calling estimates for -$0.6/share with the difference of -0.18 depicting the surprise of -30.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Aprea Therapeutics Inc. [NASDAQ:APRE] is 7.50.

Insider Stories

The most recent insider trade was by 5AM Ventures IV, L.P., Former 10% holder, and it was the sale of 0.17 million shares on Oct 05. KDev Investments AB, the 10% Owner, completed a sale of 0.24 million shares on Jul 07. On Jun 16, ROCKLAGE SCOTT M, Director, completed a sale of 0.12 million shares.